Retina Implant
Homepage - www.retina-implant.de
About Retina Implant
Retina Implant AG was a German medical technology company focused on developing treatments for individuals with retinal degenerative conditions like retinitis pigmentosa. The company's genesis dates back to 1995, when research led by Professor Eberhart Zrenner began exploring the use of electronic implants to substitute for damaged photoreceptors. This foundational work, which received a significant grant from the German Federal Ministry of Research and Education in 1996, culminated in the establishment of Retina Implant AG in 2003 by Dr. Zrenner and his colleagues, with the backing of private investors. The company's primary objective was to create a functional electronic retinal implant to restore a degree of vision to the blind.
The company's core products were the Alpha IMS and its successor, the Alpha AMS, both subretinal implants designed for patients who had lost their sight to retinitis pigmentosa. The Alpha AMS, an advanced version, featured a 4.0 mm x 3.2 mm x 70 µm microchip with 1,600 photodiodes that converted light into electrical signals to stimulate the retina. This technology aimed to replace the function of damaged photoreceptors, allowing patients to perceive light, recognize large objects, and in some cases, read letters and identify facial expressions. The Alpha IMS received its CE mark in July 2013, followed by the Alpha AMS in March 2016, permitting their commercial use in Europe. The business model revolved around the manufacturing and sale of these high-tech medical devices, targeting a very specific client base of patients with end-stage retinitis pigmentosa. In 2016, the company secured €26 million in a private funding round to expand its clinical centers and pursue reimbursement applications.
Despite its technological advancements and securing significant funding, Retina Implant AG ceased operations, with shareholders resolving to dissolve the company on March 19, 2019. The closure was attributed to two primary factors: the clinical results, while positive for many patients, did not meet the high expectations for enabling greater societal participation, and the company faced significant hurdles with Europe's rigid regulatory and healthcare reimbursement systems, which it described as hostile to innovation. Although the firm had sufficient financial resources for an orderly closure and ensured continued support for existing patients, its 16-year journey ended.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Feb 2016 | $29M | $114M | Undisclosed | — |
| LATE VC✓Equity / VC | Mar 2011 | $18M | $72M | Drosten Group | — |
Growth signals
Latest recorded traffic for Retina Implant is 1K monthly website visits, up 38.9% over the last three months. Retina Implant's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Retina Implant in the Reutlingen ecosystem
The Retina Implant office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Drosten Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Retina Implant on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Retina Implant’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










